(function(){var loadHandler=window['sl_{C6DEFA30-7612-4C19-8C71-E1939E05EB9B}'];loadHandler&&loadHandler(13, '<div id="spr0_1215d35"><div id="spr1_1215d35" class="kern"><img id="img4_1215d35" src="data/img5.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/><div id="svg6_1215d35" style="top:-1.309px;"><svg width="720" height="80" viewBox="0 0 720 80"><path fill="#034396" d="M0,0 h720 v79.854 h-720 Z"/></svg></div><div id="svg7_1215d35" style="left:19.334px;top:519.166px;"><svg width="27" height="13" viewBox="0 0 27 13"><path fill="#e6eaee" d="M0,0 h26.182 v12.908 h-26.182 Z"/></svg></div><div id="spr3_1215d35" style="left:28px;top:522px;"><img id="img0_1215d35" src="data/img2.png" width="9" height="6" alt="14"/></div></div><div id="spr2_1215d35" class="kern"><div id="spr4_1215d35" style="left:124.195px;top:129.776px;"><img id="img1_1215d35" src="data/img37.png" width="430" height="323" alt="" style="left:-0.209px;top:-0.097px;"/></div><div id="spr5_1215d35" style="left:198.439px;top:63.111px;"><img id="img2_1215d35" src="data/img38.png" width="513" height="71" alt="" style="left:-1.885px;top:-2.167px;"/></div><div id="svg8_1215d35" style="left:174.646px;top:400.439px;"><svg width="112" height="5" viewBox="-2.25 -1.125 112 5"><g fill="#ff0000" stroke="none"><path stroke="#ff0000" stroke-width="2.25" stroke-linecap="butt" transform="translate(-176.895691,-401.563904)" d="M176.896,402.689 H284.064"/></g></svg></div><div id="svg11_1215d35" style="left:295.911px;top:450.285px;"><svg width="83" height="5" viewBox="-2.25 -1.125 83 5"><g fill="#ff0000" stroke="none"><path stroke="#ff0000" stroke-width="2.25" stroke-linecap="butt" transform="translate(-298.160889,-451.410034)" d="M298.161,452.535 H376.307"/></g></svg></div><div id="spr6_1215d35" style="left:378.084px;top:433.094px;"><div style="width:0px;"><span id="txt0_1215d35" class="relpos" style="left:7.2px;top:1.323px;">0.6%</span></div></div><div id="spr7_1215d35" style="left:41px;top:27px;"><img id="img3_1215d35" src="data/img39.png" width="507" height="28" alt="EUS-BD for difficult biliary cannulation "/></div><div id="spr8_1215d35" style="left:610.812px;top:102.459px;"><div style="width:0px;"><span id="txt1_1215d35" class="relpos" style="left:7.2px;top:1.576px;">GIE 2016</span></div></div><div id="svg14_1215d35" style="left:18.667px;top:463.922px;"><svg width="680" height="56" viewBox="0 0 680 56"><path fill="#ffffff" d="M0,0 h680 v55.739 h-680 Z"/></svg></div><div id="spr9_1215d35" style="left:18.667px;top:463.922px;"><div style="width:0px;"><span id="txt2_1215d35" class="nokern relpos" style="left:7.2px;top:3.887px;">•</span><span id="txt3_1215d35" class="relpos" style="left:22.698px;top:1.07px;">EUS-BD might be considered as a substitute for ERCP in a tertiary-care center</span></div><div style="width:0px;"><span id="txt4_1215d35" class="nokern relpos" style="left:7.2px;top:27.887px;">•</span><span id="txt5_1215d35" class="relpos" style="left:22.698px;top:25.07px;">EUS-BD was required in only 0.6% of native papilla ERCPs</span></div></div></div></div>');})();